Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Non-Alcoholic Fatty Liver Clinical Trial

Official title:
A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) Treatment Administered Once Daily on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Status Terminated

Clinical Trial Summary

This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fatty Liver
Non-Alcoholic Fatty Liver
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT03953456
Study type	Interventional
Source	Genfit
Contact
Status	Terminated
Phase	Phase 2
Start date	August 16, 2019
Completion date	July 14, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05485714` - Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Recruiting	`NCT04302051` - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting	`NCT04190849` - European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
Not yet recruiting	`NCT06377631` - Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity	N/A
Completed	`NCT03849729` - Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery	Phase 4
Completed	`NCT03738358` - Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease	N/A
Completed	`NCT04198805` - Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	Phase 2
Enrolling by invitation	`NCT04209816` - Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia
Active, not recruiting	`NCT01787591` - Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome	N/A
Completed	`NCT05357248` - Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH	N/A